While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related ...
(Reuters) -Cassava Sciences said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory ...
The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...
(Reuters) -Cassava Sciences said on Tuesday it will discontinue the development of its experimental treatment simufilam for ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
After Cassava Sciences (SAVA) announced that top-line results from its ReFocus-ALZ Phase 3 trial with simufilam in patients with ...
Cassava said that it will discontinue all efforts to develop simufilam and expects to phase out the program by the end of the second quarter. Still, the biotechnology company said it has begun ...
Rest of World on MSN1d
What you need to know about Africa’s first AI factoryNvidia and Zimbabwean billionaire Strive Masiyiwa join hands to bring supercomputer technology to the continent.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback